Short answer
Zymeworks Inc. (ZYME) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $5M (down 90.6% year over year) with net income of −$45M.
Q2 2026 key financials · XBRL
- Revenue
- $5M
- −90.6% YoY · +90.6% QoQ
- Net income
- −$45M
- −2043.0% YoY · −1.9% QoQ
- Operating margin
- -919.0%
- EPS (diluted)
- −$0.62
- −2166.7% YoY · −5.1% QoQ
Source: XBRL data from the Zymeworks Inc. (ZYME) Q2 2026 10-Q on SEC EDGAR. USD.
Zymeworks Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added Theravance acquisition risk triggered by June 28, 2026 Merger Agreement
- Regulatory risk from HSR Act clearance, with $32.515 million reverse termination fee exposure
- Operational integration risk from retaining Theravance personnel and maintaining partner and supplier relationships
- Financial risk from planned $350 million debt financing, increasing leverage and debt-service obligations
- Market risk from BIOSECURE Act restrictions on biotechnology equipment or services from designated Chinese companies
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zymeworks Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.